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• Pharmaceutical markets in the Middle East region are attractive  
 
 
 
 
 
 
 
 
 
 
• The high spending on branded drugs is unsustainable  
 
• Publicly funded health systems – increased  
 pressure to reduce rising drug budgets 
 
• Originator (NDA) vs Generic  
 (ANDA) review process  
 requirements   
• 20-90% cheaper generics 
 
 
 
 
 
 
 
 
• The generic drug industry is responsible for making  
 more affordable and cost-saving medicines  
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• USA, as example: 
1980 – 17.3% 
1990 – 32.0% 
1997 – 43.0% 
2009 – 63.5% 
2016 – 89.0% 
 
• Generics share in Qatar: 22% 
 
• Average share in Middle East: ~28% (6% - 70%) 
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• In USA, as example, in 2007-2016, $1.7 trillion ($5billion/week) were saved 
 
 
 
 
 
 
 
 
 
• In Canada, $50,000 reduction in ICER per outcome 
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Cost saving with generics 
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• HOWEVER, economic savings are not guaranteed 
• Evaluations of economic impact of generics are mostly based on 
acquisition costs, NOT disease cost 
• Duh et al (2009), review – generic substitution of antiepileptic drugs 
may increase overall cost, due to reduced seizure control  
• Gothe et al (2015), 8 publications (antiepileptics, immunosuppressives, 
atypical neuroleptics and anticoagulants): 
• The overall economic evidence is against generics. Generics were 
associated with higher cost of:  
• Concomitant medications 
• Outpatient services costs 
• Inpatient services costs 
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• The bioequivalence limit by the FDA is 80-125% of the bioavailability of the 
originator drug 
• In USA, the limit is unchanged for Narrow Therapeutic Range (NTR) drugs 
• European guidelines provide a tightened acceptance interval of 90.00-
111.11% for NTR drugs 
• In Australia, the limit does not apply to NTR drugs, e.g.  no generic 
versions of digoxin or phenytoin, i.e. high generic consequences cost 
 
• The general economic benefit of generics cannot be denied 
• Evidence based generic use - cost of disease research 
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• In Qatar - local manufacturing is crucial, but… 
• Securing strategic trade partners other than few neighboring countries 
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